KI
ABCL icon

Kula Investments’s AbCellera Biologics ABCL Stock Holding History

Kula Investments’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$260K Buy
+34,489
New +$313K 0.06% 498

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kula Investments's ABCL Position: Q1 2023 in Review

Kula Investments opened a new position in AbCellera Biologics (ABCL) in Q1 2023: 34,489 shares worth $260K. The stake represents 0.06% of the portfolio and ranks #498 among its holdings.

183 funds tracked by Wall St. Rank hold ABCL as of Q1 2023.

  • Kula Investments held 34,489 shares of AbCellera Biologics worth $260K as of Q1 2023.
  • AbCellera Biologics was a new Kula Investments position in Q1 2023.
  • AbCellera Biologics made up 0.06% of Kula Investments's portfolio in Q1 2023, its #498 holding.
  • 183 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2023.

Based on Kula Investments's 13F filing for Q1 2023, filed 15 May 2023.